Yahoo Finance Results
- Reuters via Yahoo FinanceMay 01 15:58 PM
Shares dropped 2.8 percent to $57.22, however, on investor concerns that the company is becoming increasingly reliant on the drug, which is positioned to become the leading player in a new generation ...
- Market Watch4 days ago
Eisai Announces Data at ASCO 2018 Annual Meeting Showcasing LENVIMA® (lenvatinib) and KEYTRUDA® (pembrolizumab) Combination Therapy Under Strategic Oncology...Market Watch4 days ago
Global Psoriasis Therapeutics Market Growth Opportunities: UCB S.A, Eisai Co. Ltd., Novartis International AGMarket Watch5 days ago
- Reuters via Yahoo FinanceMay 01 10:51 AM
Drugmaker Merck & Co posted a 52.5 percent fall in first-quarter profit on Tuesday, hurt by hefty charge related to its collaboration with Eisai Co Ltd. Net income ...
- Other OTC
- CNBC via Yahoo FinanceMay 01 11:21 AM
Merck reported a better-than-expected first-quarter profit. The drugmaker's profit was driven by a more than 150 percent rise in sales of Keytruda. Revenue from the cancer drug accounted for ...
Stock analysis for Eisai Co Ltd (4523:Tokyo) including stock price, stock chart, company news, key statistics, fundamentals and company profile.
Eisai Co. Ltd. stock price, stock quotes and financial overviews from MarketWatch.
Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as “giving ...
- related to EISAI, Co., Ltd